Status:
COMPLETED
STIM+: PET Biomarker Education & Disclosure
Lead Sponsor:
University of Michigan
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Mild Cognitive Impairment
Dementia; Alzheimer's Type (Etiology)
Eligibility:
All Genders
55+ years
Phase:
NA
Brief Summary
When dementia is caused by AD, we refer to it as dementia of the Alzheimer's Type (DAT). The greatest risk factor for Alzheimer's Disease (AD) and DAT is advancing age, but DAT is not a normal part of...
Eligibility Criteria
Inclusion
- Enrolled in the Stimulation to Improve Memory Study (NCT03875326).
- Completed PET scan with amyloid and/or tau tracer success.
- Demonstrates decision-making capacity to engage in PET disclosure, or has a care partner in attendance that demonstrates decision-making capacity for the participant to engage in disclosure
- If diagnosed with DAT: must have a cognitively intact study partner (i.e., their care partner)
- If diagnosed with MCI: strongly recommended to have a cognitively intact study partner (i.e., their care partner)
Exclusion
- Active diagnosis of moderate depression or anxiety without treatment
- Newly diagnosed neurologic disease (since completion of Stimulation to Improve Memory Study activities)
Key Trial Info
Start Date :
December 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 7 2024
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT04818255
Start Date
December 10 2020
End Date
November 7 2024
Last Update
January 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Medical School, Department of Psychiatry
Ann Arbor, Michigan, United States, 48105